GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $33.86, for a total transaction of $1,693,000.00. Following the completion of the sale, the insider now owns 3,073,403 shares in the company, valued at $104,065,425.58. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Opko Health, Inc. also recently made the following trade(s):
- On Wednesday, July 31st, Opko Health, Inc. sold 88,839 shares of GeneDx stock. The shares were sold at an average price of $33.50, for a total transaction of $2,976,106.50.
- On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The shares were sold at an average price of $33.85, for a total transaction of $2,031,000.00.
- On Wednesday, July 24th, Opko Health, Inc. sold 75,000 shares of GeneDx stock. The shares were sold at an average price of $33.72, for a total transaction of $2,529,000.00.
- On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $32.61, for a total transaction of $1,630,500.00.
- On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00.
- On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.93, for a total transaction of $823,250.00.
- On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of GeneDx stock. The stock was sold at an average price of $28.24, for a total transaction of $1,019,972.32.
- On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of GeneDx stock. The stock was sold at an average price of $28.23, for a total transaction of $397,534.86.
- On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $26.63, for a total transaction of $1,331,500.00.
GeneDx Stock Performance
NASDAQ:WGS opened at $30.07 on Friday. The company has a fifty day moving average of $28.43 and a 200-day moving average of $16.51. The firm has a market capitalization of $785.43 million, a P/E ratio of -5.81 and a beta of 2.29. The company has a quick ratio of 2.99, a current ratio of 3.22 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $1.16 and a twelve month high of $35.65.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on WGS
Institutional Trading of GeneDx
Several hedge funds have recently modified their holdings of the stock. Thompson Davis & CO. Inc. increased its stake in GeneDx by 99.4% during the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after purchasing an additional 9,944 shares in the last quarter. Decheng Capital LLC bought a new stake in GeneDx during the 4th quarter valued at $285,000. PFG Investments LLC bought a new stake in GeneDx during the 1st quarter valued at $95,000. Vanguard Group Inc. increased its stake in GeneDx by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after purchasing an additional 28,678 shares in the last quarter. Finally, Gagnon Advisors LLC increased its stake in GeneDx by 41.6% during the 1st quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after purchasing an additional 62,059 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also
- Five stocks we like better than GeneDx
- 3 REITs to Buy and Hold for the Long Term
- Should You Invest in Bitcoin? Pros and Cons
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.